BioReliance Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan
Sigma-Aldrich Corporation’s BioReliance, the biologics and early-development services business under SAFC, has opened a new Clearance Services facility in Rockville, MD.
This world-class facility, commissioned on 1 August 2013, allows BioReliance to offer increased capacity and flexible scheduling while maintaining its core focus on providing industry-leading quality, expertise and value. The new US facility more than doubles the amount of space available to clients to conduct their critical downstream bioprocessing studies.
Designed with input from clients and built to complement BioReliance’s global viral clearance services capabilities, the Rockville facility features four large clearance suites with modular layouts that allow for customised laboratory setups. All studies performed at the facility are completely secure and supported by dedicated scientists and state-of-the-art chromatography equipment, such as GE Healthcare’s ÄKTA avant. Every project is fully compliant with applicable global guidelines and regulations, including those from FDA and European Medicines Agency. Completed studies receive a consolidated report that includes comprehensive titration and/or process data. BioReliance has already successfully conducted several client studies and quality audits in the new facility.
“Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance services to our clients. It’s all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience,” said Archie Cullen, president of BioReliance. “Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products.”
Clients using BioReliance’s US facility will have access to a wide range of resources, including personalised modular laboratory suites with spacious, technology-enabled lounges, unique 'suite-to-lounge' monitoring and support from industry-leading personnel.
The Rockville Clearance Services facility investment completes BioReliance’s upgrade to its global offering designed to deliver a total client solution and experience. The Stirling, Scotland (UK), Clearance Services laboratories were completely renovated and expanded in 2011.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance